Marshall Wace, LLP Aurinia Pharmaceuticals Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$7.77 - $12.27 $190,411 - $300,688	24,506 New	24,506 $190,000
Q4 2022 Feb 14, 2023	BUY	$4.11 - $8.14 $798,494 - $1.58 Million	194,281 New	194,281 $839,000
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $960,496 - $1.37 Million	-107,318 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $961,523 - $2.15 Million	-95,674 Reduced 47.13%	107,318 $1.33 Million
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $3.61 Million - $6.71 Million	202,992 New	202,992 $4.64 Million
Q3 2020 Nov 16, 2020	SELL	$13.19 - $16.66 $247,180 - $312,208	-18,740 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$14.12 - $18.33 $264,608 - $343,504	18,740 New	18,740 $303,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.